Join this session to hear the thoughts of experts who have successfully moved precision therapies from the oncology world into autoimmune diseases:

• Discussing whether the therapeutic goal should be complete depletion of peripheral B-cells or elimination of tissue resident B-cells that drive local pathology
• Addressing the risks associated at various level of depletion such as elevated BAFF
• Debating whether targeted depletion of specific pathogenic subsets is superior to non-selective deep depletion